Sensei Biotherapeutics Confirms Nasdaq Listing for Common & Preferred Stock

Ticker: SNSE · Form: 8-K · Filed: Jan 4, 2024 · CIK: 1829802

Sensei Biotherapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanySensei Biotherapeutics, Inc. (SNSE)
Form Type8-K
Filed DateJan 4, 2024
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, exchange-listing, corporate-governance

TL;DR

**SNSE confirms Nasdaq listing for common and preferred stock, routine compliance.**

AI Summary

Sensei Biotherapeutics, Inc. filed an 8-K on January 4, 2024, primarily to disclose that its Common Stock (SNSE) and Series A Preferred Stock Purchase Rights are registered on The Nasdaq Stock Market LLC. This filing is a routine update, confirming the company's continued listing on a major exchange. For investors, this matters because it signals ongoing compliance with listing requirements, maintaining liquidity and visibility for their shares.

Why It Matters

This filing confirms Sensei Biotherapeutics' continued listing on Nasdaq, which is crucial for maintaining investor access and the liquidity of its shares.

Risk Assessment

Risk Level: low — This is a routine administrative filing with no new material financial or operational information that would significantly alter the company's risk profile.

Analyst Insight

This filing is administrative and does not provide new information warranting immediate action. Investors should continue to monitor for substantive operational or financial updates.

Key Players & Entities

  • Sensei Biotherapeutics, Inc. (company) — the registrant filing the 8-K
  • The Nasdaq Stock Market LLC (company) — the exchange where Sensei Biotherapeutics' securities are registered
  • SNSE (company) — the trading symbol for Sensei Biotherapeutics' Common Stock

FAQ

What is the purpose of this 8-K filing by Sensei Biotherapeutics, Inc.?

The purpose of this 8-K filing, dated January 4, 2024, is primarily to disclose information under Regulation FD and Financial Statements and Exhibits, specifically confirming that Sensei Biotherapeutics, Inc.'s Common Stock and Series A Preferred Stock Purchase Rights are registered on The Nasdaq Stock Market LLC.

What is the trading symbol for Sensei Biotherapeutics, Inc.'s Common Stock?

The trading symbol for Sensei Biotherapeutics, Inc.'s Common Stock is SNSE, as stated in the filing under 'Title of each class' and 'Trading symbol'.

On which exchange are Sensei Biotherapeutics, Inc.'s securities registered?

Sensei Biotherapeutics, Inc.'s Common Stock and Series A Preferred Stock Purchase Rights are registered on The Nasdaq Stock Market LLC, according to the 'Name of each exchange on which registered' section of the filing.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing is January 4, 2024, as explicitly stated under 'Date of Report (Date of earliest event reported): January 4, 2024'.

Is Sensei Biotherapeutics, Inc. considered an emerging growth company according to this filing?

The filing includes a checkbox 'Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the S', but the box is not checked, nor is there any explicit statement confirming or denying its status as an emerging growth company within the provided text.

Filing Stats: 517 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-01-04 08:14:58

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 4, 2024, Sensei Biotherapeutics, Inc. (the "Company") updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 7.01 and the exhibit attached hereto are being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Sensei Biotherapeutics, Inc. corporate presentation, dated January 2024 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sensei Biotherapeutics, Inc. Date: January 4, 2024 /s/ Christopher W. Gerry Christopher W. Gerry General Counsel and Secretary 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.